See the DrugPatentWatch profile for Fulvestrant
What does “fulvestrant 505(b)(2)” mean?
“Fulvestrant 505(b)(2)” refers to a type of drug approval pathway in the US FDA system. The “505(b)(2)” pathway lets an applicant rely in part on existing information (for example, from published literature or from prior FDA reviews) instead of producing all clinical data from scratch for every part of the application. This pathway is used when a new product has differences from a previously approved drug but can still lean on prior evidence for safety and effectiveness.
Fulvestrant is a hormone therapy used for certain cancers that depend on estrogen signaling. The “505(b)(2)” label typically signals that the specific fulvestrant product being referenced (often a generic or modified formulation) is not identical to the original reference product and is being reviewed using this “mixed-old-and-new” evidence approach.
How is a 505(b)(2) product different from a standard generic (ANDA)?
A typical “generic” route (ANDA) generally requires demonstrating bioequivalence to a reference listed drug. A 505(b)(2) application can take a more flexible approach: it may reference the original drug’s data while also adding new studies to address differences (for example, formulation, dosing, route, or other product-specific factors). That means a 505(b)(2) fulvestrant product may involve additional clinical, nonclinical, or bridging work beyond what’s required for a straightforward bioequivalence-only generic.
Why would someone pursue 505(b)(2) for fulvestrant?
Common reasons include changes such as formulation tweaks, manufacturing differences, or other product-specific characteristics that could affect how the drug is delivered in the body. The goal is to show the modified product is safe and works similarly (and where required, to generate new data to address what differs from the reference product).
Does 505(b)(2) affect approval timelines or risk?
Often, 505(b)(2) products can avoid repeating the full package of studies used for a totally new drug, which can reduce the amount of new data needed compared with a full “505(b)(1)” development program. But timelines and required studies still vary by how different the product is from the reference and what evidence gaps must be filled. The evidentiary mix also shapes what regulators can accept versus what must be newly demonstrated.
Which fulvestrant cancers is it used for?
Fulvestrant is used as an estrogen receptor (ER)–directed therapy in hormone receptor–positive breast cancer in certain settings (for example, metastatic or advanced disease, depending on the line of therapy and prior treatments). The exact indication depends on the specific product label and approval history for the reference and any 505(b)(2) version.
What side effects do patients usually ask about?
Patients commonly ask about side effects associated with fulvestrant therapy, which can include injection-site reactions and hormone-related effects. The specific profile and frequency can vary by product and study source, but injection-related issues are a recurring theme for fulvestrant because it is administered by injection.
What to check before comparing any “fulvestrant 505(b)(2)” product
Because multiple products can exist with different labeling, it matters to confirm:
- the exact product name and strength,
- the approved indications and dosing schedule,
- whether it is identical or different in formulation/delivery compared with the reference drug,
- the patient population described in the prescribing information.
If you meant a specific product name, what is it?
“Fulvestrant 505(b)(2)” alone can refer to the regulatory pathway rather than a unique branded or generic product. If you share the exact product name (or the NDA/ANDA number) you’re looking at, I can help interpret what that specific application indicates and how its label compares to the reference fulvestrant.